Briefing: Key Facts About Medicare Drug Price Negotiation
Strategic angle: The federal government negotiates prices for high-cost drugs under Medicare Part B and Part D.
Editorial Staff Mar 11
Medicine
Latest Medicine stories from Life.
FDA Approves Leucovorin as First Drug for Rare Genetic Disorder
This approval follows previous claims of its potential use in treating autism symptoms.
Editorial Staff Mar 11
Briefing: Opinion: I’m a medical student. RFK Jr. is right about medical school and preventive care
Strategic angle: In medical school, a student writes, she has learned to react first, focus on prevention later.
Editorial Staff Mar 11
Briefing: Meissa: Multi-modal Medical Agentic Intelligence
Strategic angle: Exploring the advancements in multi-modal large language models for medical applications.
Editorial Staff Mar 11
Briefing: Mining the dark transcriptome: Synthesizing the first potential drug molecules from long noncoding RNA
Strategic angle: A team from University of Toronto Engineering pioneers a new approach to drug discovery by synthesizing long noncoding RNA outside the cell.
Editorial Staff Mar 10
Briefing: GOP Senator Investigates FDA Over Rare Disease Drug Rejections
Strategic angle: Sen. Ron Johnson raises concerns about the FDA's handling of treatments for rare diseases after discussions with Commissioner Marty Makary.
Editorial Staff Mar 10
Briefing: What’s next for RFK Jr.’s MAHA allies on vaccine policy?
Strategic angle: A coalition of Kennedy's allies gathered to discuss vaccines, but the health secretary was rarely mentioned.
Editorial Staff Mar 10
BioNTech Founders to Depart, Form New mRNA-Focused Company
Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.
Editorial Staff Mar 10
Briefing: Golfer Woodland opens up about PTSD diagnosis
Strategic angle: Gary Woodland reveals his struggle with post-traumatic stress disorder following brain surgery.
Editorial Staff Mar 10
Briefing: Vertex says its drug successfully reduced marker of kidney disease in late-stage trial
Strategic angle: Vertex reported that its drug, acquired for $4.9 billion, halved a key marker of IgA nephropathy in late-stage trials.
Editorial Staff Mar 9
Briefing: CRISPR-based technique unlocks healing power of mitochondria for heart failure therapy
Strategic angle: A groundbreaking approach using CRISPR technology shows promise in treating heart failure by enhancing mitochondrial function.
Editorial Staff Mar 9
Briefing: Unlocking the hidden pocket on a billion‑dollar drug target
Strategic angle: Researchers discover new functions of the cereblon protein that could enhance cancer drug efficacy.
Editorial Staff Mar 9
Briefing: A setback for Roche’s breast cancer drug
Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news
Editorial Staff Mar 9
Servier's $2.5 Billion Acquisition of Day One: Strategic Implications
Servier's acquisition of Day One Biopharmaceuticals for $2.5 billion could reshape its position in the pediatric oncology market, but risks remain.
Editorial Staff Mar 6
Strategic view: FDA-UniQure Tussle and Pfizer's Obesity Drug Approval in China
Strategic implications in focus: China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded.
Editorial Staff Mar 6